BioNexus Gene Lab (BGLC) Non-Current Assets (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Non-Current Assets data on file, last reported at $3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 30.87% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (up 30.87% YoY), and the FY2025 full-year result was $3.8 million, up 26.66% from the prior year.
• Non-Current Assets improved to $3.8 million in Q1 2026, from $3.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $4.0 million in Q3 2024 to a low of $2.0 million in Q3 2025.
• A 5-year average of $3.0 million and a median of $3.0 million in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets jumped 33.75% in 2023 and sank 49.58% in 2025, its largest moves.
• Tracing BGLC's Non-Current Assets over 5 years: stood at $2.7 million in 2022, then grew by 23.35% to $3.4 million in 2023, then declined by 10.43% to $3.0 million in 2024, then climbed by 26.66% to $3.8 million in 2025, then rose by 1.06% to $3.8 million in 2026.
• Business Quant data shows BGLC's Non-Current Assets at $3.8 million in Q1 2026, $3.8 million in Q4 2025, and $2.0 million in Q3 2025.